News-Medical.Net10h
Natural product derivative demonstrates promising therapeutic potential for psoriasis
Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...
Dermatology Advisor13h
Dermatologists Frequently Underestimate Psoriasis Severity
Less than a quarter of patients diagnosed with mild psoriasis had a body surface area of less than 3% at the time of diagnosis.
Dermatology Advisor14h
Risankizumab May Be Superior to Other Biologic Therapies in Plaque Psoriasis
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Healio15h
IL-23 inhibitors may reduce psoriatic arthritis risk among patients with psoriasis
Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...
Clinical Advisor5d
How Does COVID-19 Affect Adults With Atopic Dermatitis, Psoriasis, or Vitiligo?
Researchers studied the relationship between 3 dermatological immune-mediated inflammatory diseases and COVID-19.